A Multi-national Phase III Clinical Study Comparing NK105 Versus Paclitaxel in Patients With Metastatic or Recurrent Breast Cancer
Phase of Trial: Phase III
Latest Information Update: 07 Feb 2017
At a glance
- Drugs NK 105 (Primary) ; Paclitaxel
- Indications Breast cancer
- Focus Registrational; Therapeutic Use
- Sponsors Nippon Kayaku
- 01 Feb 2017 Status changed from active, no longer recruiting to completed.
- 23 Feb 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov.
- 23 Feb 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Dec 2017 as reported by ClinicalTrials.gov.